CC expands its low-GWP Opteon refrigerant portfolio to meet rising cooling needs from AI-driven data centers and support decarbonization goals.

Birkenstock (BIRK) shares surged following the release of its Q3 results for June, showing a 13% year-over-year revenue increase to €719.5 million. Although t

LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay Wolke & Rotter LLP, a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of The Chemours Company (“Chemours” or the “Company”) (NYSE: CC) investors concerning the Company's possible violations of the federal securities laws. IF YOU ARE AN INVESTOR WHO LOST MONEY ON CHEMOURS COMPANY (CC), CLICK HERE TO INQUIRE ABOUT POTENTIALLY PURSUING CLAIMS TO RECOVER YOUR LOSS. What Happened? On Augus.

[url="]Glancy Prongay Wolke and Rotter LLP[/url], a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf

BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith announces an investigation on behalf of The Chemours Company (“Chemours” or the “Company”) (NYSE: CC) investors concerning the Company's possible violations of federal securities laws. IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN THE CHEMOURS COMPANY (CC), CONTACT THE LAW OFFICES OF HOWARD G. SMITH ABOUT POTENTIALLY PURSUING CLAIMS TO RECOVER YOUR LOSS. Contact the Law Offices of Howard G. Smith to discuss your legal rights by emai.

CC's Q2 loss narrows, but lower volumes and sales weigh on results as it outlines a cautious Q3 outlook.

New additions to the Opteon™ portfolio support high-performance, sustainable cooling solutions in stationary chillers for AI-driven data centers, and commercial HVAC applications WILMINGTON, Del., Aug. 10, 2026 /PRNewswire/ -- The Chemours Company (Chemours) (NYSE: CC), a global chemistry company, today announced the launch of Opteon™ ZE (R-1234ze(E)) and Opteon™ 515B (R-515B) for stationary chiller applications.

CNC, DAR, GD, FCEL and CC stocks show how women-led companies are redefining growth with discipline, agility and results.

Chemours is upgraded to 'BUY' with a $20 PT and $30 fair value, reflecting renewed upside after recent volatility. CC's recent rally was driven by sentiment, not fundamentals, but the company now shows improving liquidity, debt reduction, and solid EBITDA guidance. Risks remain from regulatory liabilities and elevated leverage, but CC's divestment plan and Opteon growth support a high-conviction turnaround thesis.

The Chemours Company (CC) Q2 2026 Earnings Call Transcript